保留C肽分泌与成人1型糖尿病闪烁监测中更少低血糖事件和更低血糖变异性相关
横断面研究纳入290名使用闪烁监测的成人1型糖尿病患者,比较低C肽(<10 pmol/l)与持续C肽(10-200 pmol/l或10-50 pmol/l)者的监测指标。持续C肽者血糖<3.9 mmol/l时间比例、低血糖事件数、血糖标准差和变异系数均更低,且独立于糖尿病病程和估算HbA1c。持续C肽还与更低的自我报告无症状低血糖率相关。
要点
- 持续C肽(10-200 pmol/l)者血糖<3.9 mmol/l时间比例为3% vs 5%,低血糖事件为7 vs 10次/2周。
- 持续C肽者血糖标准差为3.8 vs 4.1 mmol/l,变异系数为38.0 vs 41.8。
- 持续C肽与自我报告无症状低血糖率更低相关(8.0% vs 22.8%,p=0.028)。
核心结论
- 保留C肽分泌与闪烁监测中更少的低血糖事件和更低的血糖变异性相关。
- 这提示保留C肽的个体可能更安全地达到强化血糖目标。
研究设计与样本
- 横断面研究,纳入290名在某大学教学医院糖尿病门诊就诊的成人1型糖尿病患者,使用闪烁监测且过去2年内有随机血浆C肽结果。
- 比较低C肽(<10 pmol/l)与持续C肽(10-200 pmol/l或10-50 pmol/l)者之间的闪烁监测变量。
- 另外评估了自我报告低血糖与C肽的关系(n=167)。
- 数据以中位数(四分位距)表示。
主要发现
- 持续C肽(10-200 pmol/l)者糖尿病病程更短(15 [9-24] vs 25 [15-34]年,p<0.001),诊断年龄更大(23 [14-28] vs 15 [9-25]岁,p<0.001),当前年龄无差异。
- 持续C肽与更低的血糖<3.9 mmol/l时间比例相关(3% [2-6%] vs 5% [3-9%],p<0.001)。
- 持续C肽与更少的每2周低血糖事件相关(7 [4-10] vs 10 [5-16],p<0.001)。
- 持续C肽与更低的血糖标准差(3.8 [3.4-4.2] vs 4.1 [3.5-4.7] mmol/l,p=0.017)和变异系数(38.0 [35.0-41.6] vs 41.8 [36.5-45.8],p<0.001)相关。
- 这些差异在C肽10-50 pmol/l者中也存在,且logistic回归分析中独立于糖尿病病程和估算HbA1c。
关键数值与推荐
- 低C肽定义为<10 pmol/l;持续C肽定义为10-200 pmol/l或10-50 pmol/l。
- 持续C肽(10-200 pmol/l)者血糖<3.9 mmol/l时间比例中位数3%(IQR 2-6%)vs 低C肽者5%(IQR 3-9%),p<0.001。
- 持续C肽者每2周低血糖事件中位数7次(IQR 4-10)vs 低C肽者10次(IQR 5-16),p<0.001。
- 持续C肽者血糖标准差中位数3.8 mmol/l(IQR 3.4-4.2)vs 低C肽者4.1 mmol/l(IQR 3.5-4.7),p=0.017。
- 持续C肽者血糖变异系数中位数38.0(IQR 35.0-41.6)vs 低C肽者41.8(IQR 36.5-45.8),p<0.001。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS/HYPOTHESIS: We aimed to assess whether persistence of C-peptide secretion is associated with less glucose variability and fewer low-glucose events in adults with type 1 diabetes who use flash monitoring. METHODS: We performed a cross-sectional study of 290 adults attending a university teaching hospital diabetes clinic, with type 1 diabetes, who use flash monitoring and in whom a random plasma C-peptide was available in the past 2 years. Variables relating to flash monitoring were compared between individuals with low C-peptide (<10 pmol/l) and those with persistent C-peptide (either 10-200 pmol/l or 10-50 pmol/l). In addition, the relationship between self-reported hypoglycaemia and C-peptide was assessed (n = 167). Data are median (interquartile range). RESULTS: Individuals with preserved C-peptide secretion (10-200 pmol/l) had shorter duration of diabetes (15 [9-24] vs 25 [15-34] years, p < 0.001) and older age at diagnosis (23 [14-28] vs 15 [9-25] years, p < 0.001), although current age did not differ in this cohort. Preserved C-peptide was associated with lower time with glucose <3.9 mmol/l (3% [2-6%] vs 5% [3-9%], p < 0.001), fewer low-glucose events per 2 week period (7 [4-10] vs 10 [5-16], p < 0.001), lower SD of glucose (3.8 [3.4-4.2] vs 4.1 [3.5-4.7] mmol/l, p = 0.017) and lower CV of glucose (38.0 [35.0-41.6] vs 41.8 [36.5-45.8], p < 0.001). These differences were also present in those with C-peptide 10-50 pmol/l and associations were independent of diabetes duration and estimated HbA1c in logistic regression analysis. Preserved C-peptide was also associated with lower rates of self-reported asymptomatic hypoglycaemia (8.0% vs 22.8% in the past month, p = 0.028). CONCLUSIONS/INTERPRETATION: Preserved C-peptide secretion is associated with fewer low-glucose events and lower glucose variability on flash monitoring. This suggests that individuals with preserved C-peptide may more safely achieve intensive glycaemic targets.
引用
- Gibb FW, McKnight JA, Clarke C, et al. Preserved C-peptide secretion is associated with fewer low-glucose events and lower glucose variability on flash glucose monitoring in adults with type 1 diabetes. Diabetologia. 2020. PMID: 32034440. doi:10.1007/s00125-020-05099-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。